Expression of Pax2 and E-cadherin in renal cell carcinoma: correlation with clinicopathologic parameters
10.3760/cma.j.issn.1008-1372.2017.02.018
- VernacularTitle:Pax2和E-cadherin在肾细胞癌中的表达及其相关性研究
- Author:
Cheng XU
;
Huarong LUO
;
Haihong ZHENG
;
Meifu GAN
- Keywords:
PAX2 transcription factor/ME;
Cadherins/ME;
Kidney neoplasms/ME
- From:
Journal of Chinese Physician
2017;19(2):235-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of paired box 2 (Pax2) and E-cadherin in human renal cell carcinoma (RCC) and their correlation with clinicopathologic parameters.Methods The RCC tissue microarrays containing 85 renal cell carcinoma specimens and 35 normal kidney tissue specimens were used to detect Pax2 and E-cadherin expressions by immunohistochemistry.Results The positive expression rate of Pax2 was 77.6％ (66/85) in RCC specimens,which was significantly higher than that in 35 normal kidney tissue specimens (P ＜ 0.01).The positive expression rate of E-cadherin was 30.6％ (26/85) in RCC specimens,which was significantly lower than that in 35 normal kidney tissue specimens (P ＜ 0.01).The expression of Pax2 in RCC was significantly related to histological classification and pathological grade (P ＜ 0.05),while it was not related to the size of tumor and clinical stage (P ＞ 0.05).The expression of E-cadherin in RCC was significantly related to the size of tumor,histological classification,pathological grade and clinical stage (P ＜ 0.05).The positive expression rate of E-cadherin in survival group was significantly higher than that in death group (P ＜ 0.05).Conclusions The abnormal expressions of Pax2 and E-cadherin may play a crucial stage in development of human RCC.Detection of the expressions of Pax2 and E-cadherin can be used in the evaluation of malignant degree and prognosis of RCC.
